Pfizer Biontech

Pfizer-BioNTech said Thursday they will test a combined coronavirus and influenza vaccine, which could potentially pave the way for better inoculation uptake for both illnesses.

Moderna said Friday it is suing rival vaccine makers Pfizer and BioNTech, alleging the partners infringed on its patents in developing their shot for COVID-19.

Europe's medicines watchdog said Wednesday it has started to review an adapted version of Pfizer/BioNTech's anti-Covid jab in order to better protect against specific variants of the virus, including Omicron.

Pfizer and BioNTech on Thursday announced positive results from a clinical trial on the safety and immune response of a third dose of their Covid vaccine in children aged five through 11, adding they would soon seek regulatory authorization.

Pfizer and BioNTech announced Tuesday they had formally asked the United States drug regulator for emergency approval of a second booster shot of their Covid vaccine for people aged 65 and older.

Pfizer and BioNTech will soon ask US regulators for emergency authorization for a Covid-19 vaccine for children aged five and under, US media reported Tuesday.

Pfizer and BioNTech have begun enrollment for a clinical trial to test the safety and immune response of their Omicron-specific Covid-19 vaccine in adults aged up to 55, the companies said in a statement Tuesday.

A two-dose course of Pfizer Inc. and BioNTech SE's Covid-19 shot as well as a previous infection with the disease may give stronger protection against the omicron variant, scientists from the Africa Health Research Institute in South Africa said.

The earliest studies on omicron are in and the glimpse they're providing is cautiously optimistic: while vaccines like the one made by Pfizer Inc. and BioNTech SE may be less powerful against the new variant, protection can be fortified with boosters

Pfizer Inc. and BioNTech SE said initial lab studies show a third dose of their Covid-19 vaccine may be needed to neutralize the omicron variant, results that will accelerate booster-shot drives around the world and may lead to use of new strain-spec

Pfizer and BioNTech SE said initial lab studies show a third dose of their Covid-19 vaccine may be needed to neutralize the omicron variant, results that will accelerate booster-shot drives around the world.

Two doses of the BioNTech and Pfizer coronavirus vaccine may not be enough to protect against the Omicron variant, the companies warned Wednesday, but stressed it was "still effective" after a third jab.

The EU's main Covid vaccine provider, BioNTech/Pfizer, will have jabs available for children in the bloc in two weeks' time, European Commission chief Ursula von der Leyen said Wednesday.

Germany's BioNTech said Friday it was urgently studying how well the coronavirus vaccine it developed with Pfizer protects against the new B.1.1.529 variant detected in South Africa.

Pfizer and BioNTech said Monday their COVID-19 vaccine remained 100 percent effective in children 12 to 15 years old, four months after the second dose.

Pfizer-BioNTech said Thursday they will test a combined coronavirus and influenza vaccine, which could potentially pave the way for better inoculation uptake for both illnesses.

Moderna said Friday it is suing rival vaccine makers Pfizer and BioNTech, alleging the partners infringed on its patents in developing their shot for COVID-19.

Europe's medicines watchdog said Wednesday it has started to review an adapted version of Pfizer/BioNTech's anti-Covid jab in order to better protect against specific variants of the virus, including Omicron.

Pfizer and BioNTech on Thursday announced positive results from a clinical trial on the safety and immune response of a third dose of their Covid vaccine in children aged five through 11, adding they would soon seek regulatory authorization.

Pfizer and BioNTech announced Tuesday they had formally asked the United States drug regulator for emergency approval of a second booster shot of their Covid vaccine for people aged 65 and older.

Pfizer and BioNTech will soon ask US regulators for emergency authorization for a Covid-19 vaccine for children aged five and under, US media reported Tuesday.

Pfizer and BioNTech have begun enrollment for a clinical trial to test the safety and immune response of their Omicron-specific Covid-19 vaccine in adults aged up to 55, the companies said in a statement Tuesday.

A two-dose course of Pfizer Inc. and BioNTech SE's Covid-19 shot as well as a previous infection with the disease may give stronger protection against the omicron variant, scientists from the Africa Health Research Institute in South Africa said.

The earliest studies on omicron are in and the glimpse they're providing is cautiously optimistic: while vaccines like the one made by Pfizer Inc. and BioNTech SE may be less powerful against the new variant, protection can be fortified with boosters

Pfizer Inc. and BioNTech SE said initial lab studies show a third dose of their Covid-19 vaccine may be needed to neutralize the omicron variant, results that will accelerate booster-shot drives around the world and may lead to use of new strain-spec

Pfizer and BioNTech SE said initial lab studies show a third dose of their Covid-19 vaccine may be needed to neutralize the omicron variant, results that will accelerate booster-shot drives around the world.

Two doses of the BioNTech and Pfizer coronavirus vaccine may not be enough to protect against the Omicron variant, the companies warned Wednesday, but stressed it was "still effective" after a third jab.

The EU's main Covid vaccine provider, BioNTech/Pfizer, will have jabs available for children in the bloc in two weeks' time, European Commission chief Ursula von der Leyen said Wednesday.

Germany's BioNTech said Friday it was urgently studying how well the coronavirus vaccine it developed with Pfizer protects against the new B.1.1.529 variant detected in South Africa.

Pfizer and BioNTech said Monday their COVID-19 vaccine remained 100 percent effective in children 12 to 15 years old, four months after the second dose.